Date:6/2/2008

nslational approach to medicine is taking hold at medical schools and hospitals around the country. For instance, the National Institutes of Health, the US government's medical research body, launched its Roadmap for Medical Research to establish a call for scientists to move beyond the confines of their own discipline and explore new organizational models for team science.

"Translational medicine is the future, as we know it," Nepom said. "FOCIS has been the voice of translational immunology and we're very excited that this idea beginning to change the way we view medicine."

For more information about FOCIS 2008 and program scheduling, visit HYPERLINK "http://www.focisnet.org/" http://www.focisnet.org.

'/>"/>

SOURCE Federation of Clinical Immunology Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
4. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
5. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
6. Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection
7. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
8. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
9. Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Dont Vaccinate
10. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
11. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX